# VK2735

Canonical source: https://retacompare.com/encyclopedia/vk2735

Dual GLP-1 / GIP receptor agonist comparable in mechanism to Tirzepatide.

Reference facts

Also known asViking VK2735CategoryGLP-1 & MetabolicMechanism of actionDual GLP-1 / GIP receptor agonist comparable in mechanism to Tirzepatide.TargetsGLP-1R, GIPRIndications under research or approvedObesityRegulatory status (reference entry)Investigational (Phase 3 VANQUISH for SC; Phase 2 VENTURE for oral)Half-life~5 days (subcutaneous)Sequence notesDual GLP-1 / GIP receptor agonist available in subcutaneous (weekly) and oral tablet formulations.Originator / sponsorViking TherapeuticsFirst reported2023
    Primary References

VK2735 SC Phase 2 VENTURE, presented ENDO 2024


    Explore research articles about VK2735


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- VK2735 SC Phase 2 VENTURE, presented ENDO 2024: https://www.vikingtherapeutics.com/pipeline/metabolic-disease/